Renal, Cardiovascular and Safety Outcomes of Canagliflozin in Patients with Type 2 Diabetes and Nephropathy in East and Southeast Asian Countries: Results from the CREDENCE Trial

ConclusionIn the CREDENCE trial, the risk of renal and cardiovascular events was safely reduced in participants from EA countries at high risk of renal events.

Source: Journal of Diabetes Investigation - July 2, 2021 Category: Endocrinology Authors: Takashi Wada, Kazumi Mori ‐Anai, Yutaka Kawaguchi, Hideyuki Katsumata, Hidetaka Tsuda, Mitsutaka Iida, Kenji Arakawa, Meg J. Jardine Tags: ORIGINAL ARTICLE Source Type: research